Α-Galactosidase: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 30: | Line 30: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
== Α-Galactosidase == | |||
<gallery> | |||
File:3a5v.jpg|Α-Galactosidase | |||
File:Reaction mechanism for human α-GAL.png|Α-Galactosidase | |||
File:MEL.jpg|Α-Galactosidase | |||
</gallery> | |||
Latest revision as of 00:35, 20 February 2025
Α-Galactosidase is an enzyme that hydrolyzes terminal, non-reducing α-D-galactose residues in α-D-galactosides, including substrates like melibiose, raffinose, and stachyose. It is encoded by the GLA gene in humans.
Function[edit]
Α-Galactosidase is a glycoside hydrolase involved in the breakdown of certain complex carbohydrates. It catalyzes the removal of terminal α-galactose residues, a critical step in the metabolism of certain oligosaccharides and glycolipids.
Clinical significance[edit]
Deficiency of α-Galactosidase is linked to Fabry disease, a rare genetic disorder characterized by a buildup of a particular type of fat in the body's cells. This can lead to a wide range of symptoms, including pain, skin rashes, kidney problems, and heart disease.
Therapeutic use[edit]
Recombinant human α-Galactosidase, marketed as Agalsidase beta and Agalsidase alfa, is used as an enzyme replacement therapy for Fabry disease.
See also[edit]
References[edit]
<references />
External links[edit]
Α-Galactosidase[edit]
-
Α-Galactosidase
-
Α-Galactosidase
-
Α-Galactosidase
